We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

There are two different approaches to designing an AIDS vaccine. One focuses on spurring the body to make armies of killer T cells — the 'foot soldiers' of our cell-based immune response — that track down and destroy cells that have been infiltrated by a viral invader.

The other stimulates the production of antibodies, which can in theory lock onto viruses in the bloodstream and prevent them from infecting their target cells.

In this article, Erika Check explores the pitfalls and advantages of both approaches and reports that ultimately, many vaccine developers believe that success may come from a combination of vaccines that stimulate both cellular immunity and the production of antibodies.

Link to Nature article

Reference: Nature 423, 912 (2003)

Related topics